Natixis Advisors LLC Sells 7,064 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Natixis Advisors LLC trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 109,938 shares of the biopharmaceutical company’s stock after selling 7,064 shares during the period. Natixis Advisors LLC owned 0.10% of Regeneron Pharmaceuticals worth $78,312,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Greykasell Wealth Strategies Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $504,000. Intact Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $356,000. Atala Financial Inc acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $154,000. Madison Investment Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $4,591,000. Finally, Thompson Siegel & Walmsley LLC boosted its position in shares of Regeneron Pharmaceuticals by 2.2% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 7,652 shares of the biopharmaceutical company’s stock worth $5,451,000 after buying an additional 162 shares during the period. 83.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on REGN shares. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Bernstein Bank dropped their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Citigroup dropped their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Trading Down 2.0 %

Shares of Regeneron Pharmaceuticals stock opened at $666.87 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The firm has a market cap of $72.91 billion, a PE ratio of 17.42, a PEG ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a 50 day simple moving average of $694.91 and a two-hundred day simple moving average of $833.75.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm earned $11.86 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.53%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.